Assessment in Mice of the Therapeutic Potential of Tailored, Multivalent Shiga Toxin Carbohydrate Ligands
Citations Over TimeTop 10% of 2003 papers
Abstract
The therapeutic potential of 2 soluble multivalent receptor-based inhibitors of Shiga toxin (Stx) 1 and Stx2 was determined in mice. One of these, Starfish, protected mice when it was injected subcutaneously in admixture with a lethal dose of Stx1 but not Stx2. Starfish also reduced the distribution of (125)I-Stx1 but not (125)I-Stx2 to the murine kidney and brain. A modified version of Starfish, called "Daisy," in which the Stx alpha Gal(1,4)beta Gal(1,4)beta Glc receptors were installed on the core glucose structure via a modified tethering strategy, protected mice against both Stx1 and Stx2. Daisy also protected streptomycin-treated mice from Escherichia coli O91:H21 and did not interfere with the ability of the murine immune system to produce Stx-specific protective antibodies. These results extend the possibility of using soluble carbohydrate-based receptor inhibitors to prevent Stx-mediated complications arising from infections with enterohemorrhagic E. coli serotypes.
Related Papers
- → From Farm to Table: Follow-Up of Shiga Toxin-Producing Escherichia coli Throughout the Pork Production Chain in Argentina(2016)46 cited
- → Detection of Shiga toxin-encoding genes in small community water supplies(2020)8 cited
- → Prevalence, O-genotype and Shiga toxin (Stx) 2 subtype of Stx-producing <i>Escherichia coli</i> strains isolated from Argentinean beef cattle(2021)5 cited
- Detection of Escherichia coli O157:H7 prevalence in foods of animal origin by cultural methods and PCR technique(2010)
- → Identification of serotypes and virulence markers (stx) of Escherichia coli isolated from patients with diarrhea in Shiraz, Iran(2016)3 cited